{"id":"leucovorin","rwe":[],"_fda":{"id":"2890b03c-dbef-4db8-8b07-c042d7765677","set_id":"1cb701ca-2478-4268-9d69-80293965d59d","openfda":{"unii":["RPR1R4C0P4"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["237788","1803932","1803937"],"spl_id":["2890b03c-dbef-4db8-8b07-c042d7765677"],"brand_name":["LEUCOVORIN CALCIUM"],"spl_set_id":["1cb701ca-2478-4268-9d69-80293965d59d"],"package_ndc":["67457-528-10","67457-529-20","67457-530-35"],"product_ndc":["67457-528","67457-529","67457-530"],"generic_name":["LEUCOVORIN CALCIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LEUCOVORIN CALCIUM"],"manufacturer_name":["Mylan Institutional LLC"],"application_number":["ANDA203800"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. LEUCOVORIN MAY BE HARMFUL OR FATAL IF GIVEN INTRATHECALLY. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin. Delayed methotrexate excretion may be caused by a third space fluid accumulation (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of leucovorin or prolonged administration may be indicated. Doses higher than those recommended for oral use must be given intravenously. Because of the benzyl alcohol contained in certain diluents used for reconstituting Leucovorin Calcium for Injection, when doses greater than 10 mg/m 2 are administered, Leucovorin Calcium for Injection should be reconstituted with Sterile Water for Injection, USP, and used immediately (see DOSAGE AND ADMINISTRATION section). Because of the calcium content of the leucovorin solution, no more than 160 mg of leucovorin should be injected intravenously per minute (16 mL of a 10 mg/mL, or 8 mL of a 20 mg/mL solution per minute). Leucovorin enhances the toxicity of 5-fluorouracil. When these drugs are administered concurrently in the palliative therapy of advanced colorectal cancer, the dosage of 5-fluorouracil must be lower than usually administered. Although the toxicities observed in patients treated with the combination of leucovorin plus 5-fluorouracil are qualitatively similar to those observed in patients treated with 5-fluorouracil alone, gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more commonly and may be more severe and of prolonged duration in patients treated with the combination. In the first Mayo/NCCTG controlled trial, toxicity, primarily gastrointestinal, resulted in 7% of patients requiring hospitalization when treated with 5-fluorouracil alone or 5-fluorouracil in combination with 200 mg/m 2 of leucovorin and 20% when treated with 5-fluorouracil in combination with 20 mg/m 2 of leucovorin. In the second Mayo/NCCTG trial, hospitalizations related to treatment toxicity also appeared to occur more often in patients treated with the low dose leucovorin/5-fluorouracil combination than in patients treated with the high dose combination -11% versus 3%. Therapy with leucovorin and 5-fluorouracil must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity, until those symptoms have completely resolved. Patients with diarrhea must be monitored with particular care until the diarrhea has resolved, as rapid clinical deterioration leading to death can occur. In an additional study utilizing higher weekly doses of 5-fluorouracil and leucovorin, elderly and/or debilitated patients were found to be at greater risk for severe gastrointestinal toxicity. Seizures and/or syncope have been reported rarely in cancer patients receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in those with CNS metastases or other predisposing factors, however, a causal relationship has not been established. 5 The concomitant use of leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection was associated with increased rates of treatment failure and morbidity in a placebo-controlled study."],"pregnancy":["Pregnancy Teratogenic Effects: Pregnancy Category C Adequate animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Leucovorin should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE Excessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists."],"references":["REFERENCES 1. Poon, MA, et al. Biochemical Modulation of Fluorouracil: Evidence of Significant Improvement of Survival and Quality of Life in patients with Advanced Colorectal Carcinoma, J Clin Oncol 1989; 7:1407-1418. 2. Poon, MA, et al. Biochemical Modulation of Fluorouracil with Leucovorin: Confirmatory Evidence of Improved Therapeutic Efficacy in Advanced Colorectal Cancer, J Clin Oncol 1991; 9, 11:1967-1972. 3. Grem, J.L., Shoemaker, D.D., Petrelli, N.J., Douglas, H.O., \"Severe and Fatal Toxic Effects Observed in Treatment with High- and Low-Dose Leucovorin Plus 5- Fluorouracil for Colorectal Carcinoma\", Cancer Treat Rep 71:1122, 1987. 4. Link, MP, Goorin, AH, Miser, AW, et al. “The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity.” N Engl J Med 1986; 314:1600-1606. 5. Meropol NJ, Creaven PJ, White RM, et al, \"Seizures Associated with Leucovorin Administration in Cancer Patients.\" JNCL 1995; 87 (1):56-58. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Bangalore, India Code No.: KR/DRUGS/KTK/28/384/2009 JUNE 2022"],"description":["DESCRIPTION Leucovorin is one of several active, chemically reduced derivatives of folic acid. It is useful as an antidote to drugs which act as folic acid antagonists. Also known as folinic acid, Citrovorum factor, or 5-formyl-5,6,7,8-tetrahydrofolic acid, this compound has the chemical designation of Calcium N -[p-[[[(6 RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1). The structural formula of leucovorin calcium is: C 20 H 21 CaN 7 O 7 M.W.=511.51 Leucovorin Calcium for Injection, USP, is a sterile product indicated for intramuscular (IM) or intravenous (IV) administration and is supplied in 100 mg, 200 mg, and 350 mg vials. Each 100 mg vial of Leucovorin Calcium for Injection, USP, when reconstituted with 10 mL of sterile diluent, contains leucovorin (as the calcium salt) 10 mg/mL. Each 200 mg vial of Leucovorin Calcium for Injection, USP, when reconstituted with 20 mL of sterile diluent, contains leucovorin (as the calcium salt) 10 mg/mL. Each 350 mg vial of Leucovorin Calcium for Injection, USP, when reconstituted with 17.5 mL of sterile diluent, contains leucovorin (as the calcium salt) 20 mg/mL. In each dosage form, one milligram of leucovorin calcium, USP contains 0.002 mmol of leucovorin and 0.002 mmol of calcium. These lyophilized products contain no preservative. The inactive ingredient is Sodium Chloride added to adjust tonicity and sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH is between 6.5 and 8.5. Reconstitute with Bacteriostatic Water for Injection, USP, which contains benzyl alcohol (see WARNINGS section), or with Sterile Water for Injection, USP. Structure"],"precautions":["PRECAUTIONS General Parenteral administration is preferable to oral dosing if there is a possibility that the patient may vomit and not absorb the leucovorin. Leucovorin has no effect on non-hematologic toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney. Since leucovorin enhances the toxicity of fluorouracil, leucovorin/5-fluorouracil combination therapy for advanced colorectal cancer should be administered under the supervision of a physician experienced in the use of antimetabolite cancer chemotherapy. Particular care should be taken in the treatment of elderly or debilitated colorectal cancer patients, as these patients may be at increased risk of severe toxicity. Laboratory Tests Patients being treated with the leucovorin/5-fluorouracil combination should have a CBC with differential and platelets prior to each treatment. During the first two courses a CBC with differential and platelets has to be repeated weekly and thereafter once each cycle at the time of anticipated WBC nadir. Electrolytes and liver function tests should be performed prior to each treatment for the first three cycles then prior to every other cycle. Dosage modifications of fluorouracil should be instituted as follows, based on the most severe toxicities: Diarrhea and/or Stomatitis WBC/mm 3 Platelets/mm 3 5-FU dose Nadir Nadir Moderate 1,000 to 1,900 25 to 75,000 decrease 20% Severe <1,000 <25,000 decrease 30% If no toxicity occurs, the 5-fluorouracil dose may increase 10%. Treatment should be deferred until WBCs are 4,000/mm 3 and platelets 130,000/mm 3 . If blood counts do not reach these levels within two weeks, treatment should be discontinued. Patients should be followed up with physical examination prior to each treatment course and appropriate radiological examination as needed. Treatment should be discontinued when there is clear evidence of tumor progression. Drug Interactions Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients. Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate. Leucovorin may enhance the toxicity of 5-fluorouracil (see WARNINGS section). Pregnancy Teratogenic Effects: Pregnancy Category C Adequate animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Leucovorin should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother. Pediatric Use See PRECAUTIONS , Drug Interactions subsection. Geriatric Use: Clinical studies of leucovorin calcium did not show differences in safety or effectiveness between subjects over 65 and younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older patients cannot be ruled out. This drug is known to be excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function. Because elder patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"how_supplied":["HOW SUPPLIED Leucovorin Calcium for Injection, USP, is supplied in sterile, single dose vials as follows: NDC 67457-528-10 100 mg boxed vial. NDC 67457-529-20 200 mg boxed vial. NDC 67457-530-35 350 mg boxed vial. Store at 20° to 25°C (68° to 77° F). [See USP Controlled Room Temperature.] Protect from light. Retain in carton until time of use."],"pediatric_use":["Pediatric Use See PRECAUTIONS , Drug Interactions subsection. Geriatric Use: Clinical studies of leucovorin calcium did not show differences in safety or effectiveness between subjects over 65 and younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older patients cannot be ruled out. This drug is known to be excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function. Because elder patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"effective_time":"20220601","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother."],"laboratory_tests":["Laboratory Tests Patients being treated with the leucovorin/5-fluorouracil combination should have a CBC with differential and platelets prior to each treatment. During the first two courses a CBC with differential and platelets has to be repeated weekly and thereafter once each cycle at the time of anticipated WBC nadir. Electrolytes and liver function tests should be performed prior to each treatment for the first three cycles then prior to every other cycle. Dosage modifications of fluorouracil should be instituted as follows, based on the most severe toxicities: Diarrhea and/or Stomatitis WBC/mm 3 Platelets/mm 3 5-FU dose Nadir Nadir Moderate 1,000 to 1,900 25 to 75,000 decrease 20% Severe <1,000 <25,000 decrease 30% If no toxicity occurs, the 5-fluorouracil dose may increase 10%. Treatment should be deferred until WBCs are 4,000/mm 3 and platelets 130,000/mm 3 . If blood counts do not reach these levels within two weeks, treatment should be discontinued. Patients should be followed up with physical examination prior to each treatment course and appropriate radiological examination as needed. Treatment should be discontinued when there is clear evidence of tumor progression."],"adverse_reactions":["ADVERSE REACTIONS Allergic sensitization, including anaphylactoid reactions and urticaria, has been reported following the administration of both oral and parenteral leucovorin. No other adverse reactions have been attributed to the use of leucovorin per se . The following table summarizes significant adverse events occurring in 316 patients treated with the leucovorin/5-fluorouracil combinations compared against 70 patients treated with 5-fluorouracil alone for advanced colorectal carcinoma. These data are taken from the Mayo/NCCTG large multicenter prospective trial evaluating the efficacy and safety of the combination regimen. PERCENTAGE OF PATIENTS TREATED WITH LEUCOVORIN/FLUOROURACIL FOR ADVANCED COLORECTAL CARCINOMA REPORTING ADVERSE EXPERIENCES OR HOSPITALIZED FOR TOXICITY (High LV*) /5-FU (Low LV † ) /5-FU 5-FU Alone (N=155) (N=161) (N=70) Any ‡ Grade 3 +§ Any ‡ Grade 3 +§ Any ‡ Grade 3 +§ (%) (%) (%) (%) (%) (%) Leukopenia 69 14 83 23 93 48 Thrombocytopenia 8 2 8 1 18 3 Infection 8 1 3 1 7 2 Nausea 74 10 80 9 60 6 Vomiting 46 8 44 9 40 7 Diarrhea 66 18 67 14 43 11 Stomatitis 75 27 84 29 59 16 Constipation 3 0 4 0 1 - Lethargy/Malaise/Fatigue 13 3 12 2 6 3 Alopecia 42 5 43 6 37 7 Dermatitis 21 2 25 1 13 - Anorexia 14 1 22 4 14 - Hospitalization for Toxicity 5% 15% 7% * High LV = Leucovorin 200 mg/m 2 † Low LV = Leucovorin 20 mg/m 2 ‡ Any = percentage of patients reporting toxicity of any severity § Grade 3+ = percentage of patients reporting toxicity of Grade 3 or higher"],"contraindications":["CONTRAINDICATIONS Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin B 12 . A hematologic remission may occur while neurologic manifestations continue to progress."],"drug_interactions":["Drug Interactions Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients. Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate. Leucovorin may enhance the toxicity of 5-fluorouracil (see WARNINGS section)."],"precautions_table":["
Diarrhea and/or StomatitisWBC/mm3Platelets/mm35-FU dose
NadirNadir
Moderate1,000 to 1,90025 to 75,000decrease 20%
Severe<1,000<25,000decrease 30%
"],"general_precautions":["General Parenteral administration is preferable to oral dosing if there is a possibility that the patient may vomit and not absorb the leucovorin. Leucovorin has no effect on non-hematologic toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney. Since leucovorin enhances the toxicity of fluorouracil, leucovorin/5-fluorouracil combination therapy for advanced colorectal cancer should be administered under the supervision of a physician experienced in the use of antimetabolite cancer chemotherapy. Particular care should be taken in the treatment of elderly or debilitated colorectal cancer patients, as these patients may be at increased risk of severe toxicity."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF). The biologically active compound of the mixture is the (-)- l -isomer, known as Citrovorum factor or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties. l -Leucovorin ( l -5-formyltetrahydrofolate) is rapidly metabolized (via 5, 10-methenyltetrahydrofolate then 5, 10-methylenetetrahydrofolate) to l ,5-methyltetrahydrofolate. l ,5-Methyltetrahydrofolate can in turn be metabolized via other pathways back to 5,10-methylenetetrahydrofolate, which is converted to 5-methyltetrahydrofolate by an irreversible, enzyme catalyzed reduction using the cofactors FADH 2 and NADPH. Administration of leucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. In contrast, leucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy, such as 5-fluorouracil. Concurrent administration of leucovorin does not appear to alter the plasma pharmacokinetics of 5-fluorouracil. 5-Fluorouracil is metabolized to fluorodeoxyuridylic acid, which binds to and inhibits the enzyme thymidylate synthase (an enzyme important in DNA repair and replication). Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme. The pharmacokinetics after intravenous, intramuscular and oral administration of a 25 mg dose of leucovorin were studied in male volunteers. After intravenous administration, serum total reduced folates (as measured by Lactobacillus casei assay) reached a mean peak of 1259 ng/mL (range 897 to 1625). The mean time to peak was 10 minutes. This initial rise in total reduced folates was primarily due to the parent compound 5-formyl-THF (measured by Streptococcus faecalis assay) which rose to 1206 ng/mL at 10 minutes. A sharp drop in parent compound followed and coincided with the appearance of the active metabolite 5-methyl-THF which became the predominant circulating form of the drug. The mean peak of 5-methyl-THF was 258 ng/mL and occurred at 1.3 hours. The terminal half-life for total reduced folates was 6.2 hours. The area under the concentration versus time curves (AUCs) for l -leucovorin, d -leucovorin and 5-methyltetrahydrofolate were 28.4 ± 3.5, 956 ± 97 and 129 ± 12 (mg/min/L ± S.E.). When a higher dose of d , l -leucovorin (200 mg/m 2 ) was used, similar results were obtained. The d-isomer persisted in plasma at concentrations greatly exceeding those of the l -isomer. After intramuscular injection, the mean peak of serum total reduced folates was 436 ng/mL (range 240 to 725) and occurred at 52 minutes. Similar to IV administration, the initial sharp rise was due to the parent compound. The mean peak of 5-formyl-THF was 360 ng/mL and occurred at 28 minutes. The level of the metabolite 5-methyl-THF increased subsequently over time until at 1.5 hours it represented 50% of the circulating total folates. The mean peak of 5-methyl-THF was 226 ng/mL at 2.8 hours. The terminal half-life of total reduced folates was 6.2 hours. There was no difference of statistical significance between IM and IV administration in the AUC for total reduced folates, 5-formyl-THF, or 5-methyl-THF. After oral administration of leucovorin reconstituted with aromatic elixir, the mean peak concentration of serum total reduced folates was 393 ng/mL (range 160 to 550). The mean time to peak was 2.3 hours and the terminal half-life was 5.7 hours. The major component was the metabolite 5-methyltetrahydrofolate to which leucovorin is primarily converted in the intestinal mucosa. The mean peak of 5-methyl-THF was 367 ng/mL at 2.4 hours. The peak level of the parent compound was 51 ng/mL at 1.2 hours. The AUC of total reduced folates after oral administration of the 25 mg dose was 92% of the AUC after intravenous administration. Following oral administration, leucovorin is rapidly absorbed and expands the serum pool of reduced folates. At a dose of 25 mg, almost 100% of the l-isomer but only 20% of the d-isomer is absorbed. Oral absorption of leucovorin is saturable at doses above 25 mg. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg. In a randomized clinical study conducted by the Mayo Clinic and the North Central Cancer Treatment Group (Mayo/NCCTG) in patients with advanced metastatic colorectal cancer three treatment regimens were compared: Leucovorin (LV) 200 mg/m 2 and 5-fluorouracil (5-FU) 370 mg/m 2 versus LV 20 mg/m 2 and 5-FU 425 mg/m 2 versus 5-FU 500 mg/m 2 . All drugs were administered by slow intravenous infusion daily for 5 days repeated every 28 to 35 days. Response rates were 26% (p=0.04 versus 5-FU alone), 43% (p=0.001 versus 5-FU alone) and 10% for the high dose leucovorin, low dose leucovorin and 5-FU alone groups respectively. Respective median survival times were 12.2 months (p=0.037), 12 months (p=0.050), and 7.7 months. The low dose LV regimen gave a statistically significant improvement in weight gain of more than 5%, relief of symptoms, and improvement in performance status. The high dose LV regimen gave a statistically significant improvement in performance status and trended toward improvement in weight gain and in relief of symptoms but these were not statistically significant. 1 In a second Mayo/NCCTG randomized clinical study the 5-FU alone arm was replaced by a regimen of sequentially administered methotrexate (MTX), 5-FU, and LV. Response rates with LV 200 mg/m 2 and 5-FU 370 mg/m 2 versus LV 20 mg/m 2 and 5-FU 425 mg/m 2 versus sequential MTX and 5-FU and LV were respectively 31% (p=<.01), 42% (p=<.01), and 14%. Respective median survival times were 12.7 months (p=<.04), 12.7 months (p=<.01), and 8.4 months. No statistically significant difference in weight gain of more than 5% or in improvement in performance status was seen between the treatment arms. 2 The pharmacokinetics of 200 mg doses of leucovorin administered intravenously and orally (reconstituted powder, not tablets) have been evaluated in healthy male subjects. The serum clearance corrected for bioavailability, terminal half-life, and apparent volume of distribution of total folate were not significantly different between routes of administration. The oral bioavailability of the 200 mg dose was 31%. Eighty-three percent of the biologically active IV dose was recovered in the urine within 24 hours, 31% as 5-methyltetrahydrofolate. Twenty percent of the same oral dose was excreted in 24 hours, 16% as 5-methyltetrahydrofolate."],"indications_and_usage":["INDICATIONS AND USAGE Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."],"laboratory_tests_table":["
Diarrhea and/or StomatitisWBC/mm3Platelets/mm35-FU dose
NadirNadir
Moderate1,000 to 1,90025 to 75,000decrease 20%
Severe<1,000<25,000decrease 30%
"],"adverse_reactions_table":["
(High LV*) /5-FU(Low LV†) /5-FU5-FU Alone
(N=155)(N=161)(N=70)
Any‡Grade 3+§Any‡Grade 3+§Any‡Grade 3+§
(%)(%)(%)(%)(%)(%)
Leukopenia691483239348
Thrombocytopenia8281183
Infection813172
Nausea7410809606
Vomiting468449407
Diarrhea661867144311
Stomatitis752784295916
Constipation30401-
Lethargy/Malaise/Fatigue13312263
Alopecia425436377
Dermatitis21225113-
Anorexia14122414-
Hospitalization for Toxicity5%15%7%
*High LV = Leucovorin 200 mg/m2†Low LV = Leucovorin 20 mg/m2‡Any = percentage of patients reporting toxicity of any severity§Grade 3+ = percentage of patients reporting toxicity of Grade 3 or higher
"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Advanced Colorectal Cancer Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m 2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m 2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m 2 by intravenous injection followed by 5-fluorouracil at 425 mg/m 2 by intravenous injection. 5-Fluorouracil and leucovorin should be administered separately to avoid the formation of a precipitate. Treatment is repeated daily for five days. This five-day treatment course may be repeated at 4 week (28-day) intervals, for 2 courses and then repeated at 4 to 5 week (28 to 35 day) intervals provided that the patient has completely recovered from the toxic effects of the prior treatment course. In subsequent treatment course, the dosage of 5-fluorouracil should be adjusted based on patient tolerance of the prior treatment course. The daily dosage of 5-fluorouracil should be reduced by 20% for patients who experienced moderate hematologic or gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity (see PRECAUTIONS : Laboratory Tests ). For patients who experienced no toxicity in the prior treatment course, 5-fluorouracil dosage may be increased by 10%. Leucovorin dosages are not adjusted for toxicity. Leucovorin Rescue After High-Dose Methotrexate Therapy The recommendations for leucovorin rescue are based on a methotrexate dose of 12 to 15 grams/m 2 administered by intravenous infusion over 4 hours (see methotrexate package insert for full prescribing information). 4 Leucovorin rescue at a dose of 15 mg (approximately 10 mg/m 2 ) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion. In the presence of gastrointestinal toxicity, nausea or vomiting, leucovorin should be administered parenterally. Do not administer leucovorin intrathecally. Serum creatinine and methotrexate levels should be determined at least once daily. Leucovorin administration, hydration, and urinary alkalization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10 -8 M (0.05 micromolar). The leucovorin dose should be adjusted or leucovorin rescue extended based on the following guidelines: GUIDELINES FOR LEUCOVORIN DOSAGE AND ADMINISTRATION DO NOT ADMINISTER LEUCOVORIN INTRATHECALLY Clinical Situation Laboratory Findings Leucovorin Dosage and Duration Normal Methotrexate Elimination Serum methotrexate level approximately 10 micromo-molar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours. 15 mg PO, IM, or IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion). Delayed Late Methotrexate Elimination Serum methotrexate level remaining above 0.2 micrommolar at 72 hours, and more than 0.05 micromolar 96 hours after administration. Continue 15 mg PO, IM, or IV q 6 hours, until methotrexate level is less than 0.05 micromolar. Delayed Early Methotrexate Elimination and/or Evidence of Acute Renal Injury Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more). 150 mg IV q 3 hours, until methotrexate level is less than 1 micromolar; then 15 mg IV q 3 hours until methotrexate level is less than 0.05 micromolar. Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure. In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved. Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe than abnormalities described in the table above. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed. Impaired Methotrexate Elimination or Inadvertent Overdosage Leucovorin rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is a delayed excretion (see WARNINGS section). Leucovorin 10 mg/m 2 should be administered IM, IV, or PO every 6 hours until the serum methotrexate level is less than 10 -8 M. In the presence of gastrointestinal toxicity, nausea, or vomiting, leucovorin should be administered parenterally. Do not administer leucovorin intrathecally. Serum creatinine and methotrexate levels should be determined at 24 hour intervals. If the 24 hour serum creatinine has increased 50% over baseline or if the 24 hour methotrexate level is greater than 5 x 10 -6 M or the 48 hour level is greater than 9 x 10 -7 M, the dose of leucovorin should be increased to 100 mg/m 2 IV every 3 hours until the methotrexate level is less than 10 -8 M. Hydration (3 L/d) and urinary alkalinization with sodium bicarbonate solution should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7.0 or greater. Megaloblastic Anemia Due to Folic Acid Deficiency Up to 1 mg daily. There is no evidence that doses greater than 1 mg/day have greater efficacy than those of 1 mg; additionally, loss of folate in urine becomes roughly logarithmic as the amount administered exceeds 1 mg. Each 100, and 200 mg vial of Leucovorin Calcium for Injection when reconstituted with 10, and 20 mL, respectively, of sterile diluent yields a leucovorin concentration of 10 mg per mL. Each 350 mg vial of Leucovorin Calcium for Injection when reconstituted with 17.5 mL of sterile diluent yields a leucovorin concentration of 20 mg per mL. Leucovorin Calcium for Injection contains no preservative. Reconstitute the lyophilized vial products with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved), or Sterile Water for Injection, USP. When reconstituted with Bacteriostatic Water for Injection, USP, the resulting solution must be used within 7 days. If the product is reconstituted with Sterile Water for Injection, USP, use immediately and discard any unused portion. Because of the benzyl alcohol contained in Bacteriostatic Water for Injection, USP, when doses greater than 10 mg/m 2 are administered, Leucovorin Calcium for Injection should be reconstituted with Sterile Water for Injection, USP, and used immediately. (See WARNINGS .) Because of the calcium content of the leucovorin solution, no more than 160 mg of leucovorin should be injected intravenously per minute (16 mL of a 10 mg/mL, or 8 mL of a 20 mg/mL solution per minute). Parenteral products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Leucovorin should not be mixed in the same infusion as 5-fluorouracil, since this may lead to the formation of a precipitate."],"spl_product_data_elements":["LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN SODIUM CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN SODIUM CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM LEUCOVORIN SODIUM CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_and_administration_table":["
Clinical SituationLaboratory FindingsLeucovorin Dosage and Duration
NormalMethotrexateEliminationSerum methotrexate level approximately 10 micromo-molar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours.15 mg PO, IM, or IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).
Delayed LateMethotrexateEliminationSerum methotrexate level remaining above 0.2 micrommolar at 72 hours, and more than 0.05 micromolar 96 hours after administration.Continue 15 mg PO, IM, or IV q 6 hours, until methotrexate level is less than 0.05 micromolar.
Delayed EarlyMethotrexateElimination and/orEvidence of Acute Renal InjurySerum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more).150 mg IV q 3 hours, until methotrexate level is less than 1 micromolar; then 15 mg IV q 3 hours until methotrexate level is less than 0.05 micromolar.
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 67457-528-10 Leucovorin Calcium for Injection 100 mg* per vial For Intravenous or Intramuscular Use Must be diluted Lyophilized Rx only Single-Dose Vial 100 mg Carton Label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 67457-529-20 Leucovorin Calcium for Injection 200 mg* per vial For Intravenous or Intramuscular Use Must be diluted Lyophilized Rx only Single-Dose Vial 200 mg Carton Label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 67457-530-35 Leucovorin Calcium for Injection 350 mg* per vial For Intravenous or Intramuscular Use Must be diluted Lyophilized Rx only Single-Dose Vial 350 mg Carton Label"]},"tags":[{"label":"Folate Analog","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dihydrofolate reductase","category":"target"},{"label":"DHFR","category":"gene"},{"label":"TYMS","category":"gene"},{"label":"V03AF03","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","category":"indication"},{"label":"Bone Marrow Suppression due to Folic Acid Antagonism","category":"indication"},{"label":"Folic acid deficiency","category":"indication"},{"label":"Megaloblastic anemia","category":"indication"},{"label":"Methotrexate Toxicity","category":"indication"},{"label":"Pyrimethamine Toxicity","category":"indication"},{"label":"Pfizer Japan Inc","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Antidotes","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Vitamin B Complex","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1707 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1316 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1078 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"1041 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"965 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"877 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"840 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"740 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"689 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"686 reports"}],"commonSideEffects":[{"effect":"Leukopenia","drugRate":"83%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"80%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"44%","severity":"common","_validated":true},{"effect":"Diarrhea","drugRate":"67%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"18%","severity":"serious","_validated":true},{"effect":"Stomatitis","drugRate":"84%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"0%","severity":"mild","_validated":true},{"effect":"Lethargy/Malaise/Fatigue","drugRate":"13%","severity":"common","_validated":true},{"effect":"Alopecia","drugRate":"43%","severity":"common","_validated":true},{"effect":"Dermatitis","drugRate":"25%","severity":"common","_validated":true},{"effect":"Anorexia","drugRate":"14%","severity":"common","_validated":true},{"effect":"Infection","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hospitalization for Toxicity","drugRate":"15%","severity":"serious","_validated":true}],"contraindications":["Cobalamin deficiency","Pernicious anemia"],"specialPopulations":{"Pregnancy":"Leucovorin should be given to pregnant woman only if clearly needed.","Geriatric use":"Clinical studies of leucovorin calcium did not show differences in safety or effectiveness between subjects over 65 and younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older patients cannot be ruled out. This drug is known to be excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function.","Paediatric use":"See PRECAUTIONS, Drug Interactions.","Renal impairment":"the risk of toxic reactions to the drug may be greater in patients with impaired renal function."}},"trials":[],"aliases":[],"company":"Pfizer Japan Inc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=leucovorin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:40.799109+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Leucovorin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:43:54.859219+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:53.510043+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:43:39.281383+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=leucovorin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:54.273683+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:37.312416+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:37.312480+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:43:55.787050+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201138/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:54.737844+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203800","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:37.312493+00:00"}},"allNames":"wellcovorin","offLabel":[],"synonyms":["sodium folinate","folinic acid","leucovorin","calcium folinate","leucovorin calcium","folinic acid calcium salt","folinic acid calcium","wellcovorin","folinic acid calcium salt pentahydrate"],"timeline":[{"date":"1952-06-20","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1983-07-08","type":"positive","source":"FDA Orange Book","milestone":"Wellcovorin approved — EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1986-01-30","type":"positive","source":"FDA Orange Book","milestone":"Leucovorin Calcium approved — EQ 5MG BASE"},{"date":"1997-04-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 12 manufacturers approved"},{"date":"2021-11-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc)"},{"date":"2026-02-03","type":"positive","source":"FDA Orange Book","milestone":"Vykoura approved — EQ 50MG BASE/5ML (EQ 10MG BASE/ML)"}],"aiSummary":"Wellcovorin, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine, and in combination with 5-fluorouracil to treat colorectal cancer. It is also used to treat folate deficiency, anemia, and methanol poisoning, and can be administered orally, by muscle injection, or through a vein.","approvals":[{"date":"1952-06-20","orphan":true,"company":"","regulator":"FDA"},{"date":"2021-11-25","orphan":false,"company":"PFIZER JAPAN INC","regulator":"PMDA"}],"brandName":"Wellcovorin","ecosystem":[{"indication":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":1900000},{"indication":"Bone Marrow Suppression due to Folic Acid Antagonism","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null},{"indication":"Folic acid deficiency","otherDrugs":[{"name":"folic acid","slug":"folic-acid","company":"Lederle"},{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null},{"indication":"Megaloblastic anemia","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null},{"indication":"Methotrexate Toxicity","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":240000},{"indication":"Pyrimethamine Toxicity","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null},{"indication":"Sulfadiazine Toxicity","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null},{"indication":"Trimethoprim Toxicity","otherDrugs":[{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Dihydrofolate reductase","novelty":"Follow-on","targets":[{"gene":"DHFR","source":"DrugCentral","target":"Dihydrofolate reductase","protein":"Dihydrofolate reductase"},{"gene":"TYMS","source":"DrugCentral","target":"Thymidylate synthase","protein":"Thymidylate synthase"}],"modality":"Small Molecule","drugClass":"Folate Analog","explanation":"","oneSentence":"","technicalDetail":"Wellcovorin competitively inhibits the binding of folic acid antagonists to dihydrofolate reductase, thereby restoring the enzyme's activity and allowing the synthesis of tetrahydrofolate, a crucial cofactor for DNA synthesis and repair."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Folinic_acid","title":"Folinic acid","extract":"Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, and may be used to treat folate deficiency, anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.","wiki_history":"== History ==\nFolinic acid was discovered as a needed growth factor for the bacterium Leuconostoc citrovorum in 1948, by Sauberlich and Baumann. This resulted in it being called \"citrovorum factor\", meaning citrovorum growth factor. It had an unknown structure, but was found to be a folate derivative that had to be metabolized in the liver before it could support the growth of L. citrovorum. The synthesis of citrovorum factor by liver cells in culture was eventually accomplished from pteroylglutamic acid in the presence of suitable concentrations of ascorbic acid. The simultaneous addition of sodium formate to such systems increased citrovorum factor activity in the cell-free supernatants (producing, as is now known, the 5-formyl derivative). From this method of preparation of large amounts of the factor, its structure as levo-folinic acid (5-formyl tetrahydrofolic acid) was eventually deduced.\n\nIn September 2025, the US Food and Drug Administration (FDA) initiated the process of approving leucovorin calcium tablets for the treatment of cerebral folate deficiency, a condition associated with developmental delays, autistic features, seizures, and movement issues. \n\nOn 10 March 2026, the FDA approved leucovorin tablets for FOLR1-related cerebral folate transport deficiency in children and adults.","wiki_society_and_culture":"== Society and culture ==\n=== Names ===\n\nFolinic acid should be distinguished from folic acid (vitamin B9). However, folinic acid is a vitamer of folic acid and has the full vitamin activity of this vitamin. Levofolinic acid and its salts are the 2S-form of the molecule. They are the only forms of the molecule that are known to be biologically active.\n\nIt is generally administered as the calcium or sodium salt (calcium folinate [INN], sodium folinate, leucovorin calcium, leucovorin sodium)."},"commercial":{"launchDate":"1952","_launchSource":"DrugCentral (FDA 1952-06-20, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1232","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=leucovorin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=leucovorin","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Folinic_acid","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:18:22.378712","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:59.953393+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"mesna","drugSlug":"mesna","fdaApproval":"1988-12-30","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dexrazoxane","drugSlug":"dexrazoxane","fdaApproval":"1995-05-26","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"levofolinic acid","drugSlug":"levofolinic-acid","fdaApproval":"2008-03-07","relationship":"same-class"},{"drugName":"amifostine","drugSlug":"amifostine","fdaApproval":"1995-12-08","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rasburicase","drugSlug":"rasburicase","fdaApproval":"2002-07-12","relationship":"same-class"},{"drugName":"palifermin","drugSlug":"palifermin","fdaApproval":"2004-12-15","relationship":"same-class"},{"drugName":"glucarpidase","drugSlug":"glucarpidase","fdaApproval":"2012-01-17","relationship":"same-class"},{"drugName":"arginine","drugSlug":"arginine","fdaApproval":"1973-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lysine","drugSlug":"lysine","fdaApproval":"","relationship":"same-class"},{"drugName":"trilaciclib","drugSlug":"trilaciclib","fdaApproval":"2021-02-12","patentExpiry":"Oct 25, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"leucovorin","indications":{"approved":[{"name":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with advanced colorectal cancer","usPrevalence":153000,"globalPrevalence":1900000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Bone Marrow Suppression due to Folic Acid Antagonism","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Folic acid deficiency","source":"DrugCentral","snomedId":190633005,"regulator":"FDA","eligibility":"Megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible"},{"name":"Megaloblastic anemia","source":"DrugCentral","snomedId":53165003,"regulator":"FDA","eligibility":"Megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible"},{"name":"Methotrexate Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"After high dose methotrexate therapy in osteosarcoma, or to counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists","prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2015[INST])"},{"name":"Pyrimethamine Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Sulfadiazine Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Trimethoprim Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Trimetrexate Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"mesna","brandName":"mesna","genericName":"mesna","approvalYear":"1988","relationship":"same-class"},{"drugId":"dexrazoxane","brandName":"dexrazoxane","genericName":"dexrazoxane","approvalYear":"1995","relationship":"same-class"},{"drugId":"levofolinic-acid","brandName":"levofolinic acid","genericName":"levofolinic acid","approvalYear":"2008","relationship":"same-class"},{"drugId":"amifostine","brandName":"amifostine","genericName":"amifostine","approvalYear":"1995","relationship":"same-class"},{"drugId":"rasburicase","brandName":"rasburicase","genericName":"rasburicase","approvalYear":"2002","relationship":"same-class"},{"drugId":"palifermin","brandName":"palifermin","genericName":"palifermin","approvalYear":"2004","relationship":"same-class"},{"drugId":"glucarpidase","brandName":"glucarpidase","genericName":"glucarpidase","approvalYear":"2012","relationship":"same-class"},{"drugId":"arginine","brandName":"arginine","genericName":"arginine","approvalYear":"1973","relationship":"same-class"},{"drugId":"lysine","brandName":"lysine","genericName":"lysine","approvalYear":"","relationship":"same-class"},{"drugId":"trilaciclib","brandName":"trilaciclib","genericName":"trilaciclib","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":["Colorectal Cancer"],"enrollment":144,"completionDate":"2028-10-01"},{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":["Pancreatic Carcinoma"],"enrollment":130,"completionDate":"2025-12"},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Advanced Malignant Solid Neoplasm","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Malignant Solid Neoplasm","Malignant Female Reproductive System Neoplasm","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":2900,"completionDate":"2030-07-01"},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":["Peritoneal Mesothelioma","Peritoneal Carcinomatosis","Ovarian Cancer","Gastrointestinal Cancer","Appendiceal Cancer","Atypical Mesothelial Proliferation","Colorectal Cancer"],"enrollment":60,"completionDate":"2031-12-30"},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":["Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma"],"enrollment":94,"completionDate":"2030-12"},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":["Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7"],"enrollment":120,"completionDate":"2027-06-01"},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":["Advanced Biliary Tract Carcinoma","Advanced Gallbladder Carcinoma","Advanced Intrahepatic Cholangiocarcinoma","Recurrent Biliary Tract Carcinoma","Recurrent Gallbladder Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":66,"completionDate":"2026-05-01"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":["Metastatic Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":["Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma"],"enrollment":180,"completionDate":"2030-10"},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":["Colon Adenocarcinoma","Stage IIA Colon Cancer AJCC v7","Stage IIB Colon Cancer AJCC v7","Stage IIC Colon Cancer AJCC v7"],"enrollment":2431,"completionDate":"2026-04-11"},{"nctId":"NCT05355701","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":["Melanoma","Non-Small-Cell Lung Cancer","Thyroid Cancer","Glioma","Advanced Colorectal Cancer (Part 1)"],"enrollment":267,"completionDate":"2030-05-06"},{"nctId":"NCT06346197","phase":"PHASE3","title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-12-08","conditions":["Gastric Cancer","MSI-H","Metastatic Cancer","Advanced Cancer"],"enrollment":132,"completionDate":"2028-05-15"},{"nctId":"NCT07283939","phase":"NA","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-13","conditions":["Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma"],"enrollment":420,"completionDate":"2030-05-02"},{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":["Pancreas Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma"],"enrollment":64,"completionDate":"2028-07"},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":["Metastatic Colorectal Cancer"],"enrollment":450,"completionDate":"2031-08-31"},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":["Ph+ ALL"],"enrollment":100,"completionDate":"2030-03-30"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":["Pancreatic Neoplasms","Neoplasm Metastasis","Hepatic Metastasis of Pancreatic Cancer"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":614,"completionDate":"2029-08-31"},{"nctId":"NCT07490301","phase":"PHASE2,PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","PDAC"],"enrollment":900,"completionDate":"2031-06"},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":["Cancer"],"enrollment":1500,"completionDate":"2029-08-25"},{"nctId":"NCT02758951","phase":"PHASE2,PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":["Colorectal Neoplasm","Colorectal Cancer","Colorectal Neoplasms Malignant","Colorectal Carcinoma","Colorectal Adenocarcinoma","Peritoneal Neoplasms","Peritoneal Carcinomatosis","Peritoneal Cancer","Peritoneal Metastases","Peritoneal Neoplasm Malignant Secondary Carcinomatosis","Peritoneal Neoplasm Malignant Secondary"],"enrollment":358,"completionDate":"2029-06-01"},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":["Metastatic Colorectal Cancer"],"enrollment":390,"completionDate":"2028-04"},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":408,"completionDate":"2034-06-30"},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":["Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8"],"enrollment":314,"completionDate":"2028-03-31"},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":176,"completionDate":"2026-12-31"},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":["Colon Adenocarcinoma","Rectal Adenocarcinoma"],"enrollment":477,"completionDate":"2030-10-27"},{"nctId":"NCT07486492","phase":"EARLY_PHASE1","title":"Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-03-31","conditions":["Colorectal Cancer Metastatic","Fecal Microbiota Transplantation"],"enrollment":10,"completionDate":"2028-01-31"},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":["Colorectal Neoplasms"],"enrollment":1000,"completionDate":"2032-01-30"},{"nctId":"NCT05179889","phase":"PHASE2,PHASE3","title":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","status":"RECRUITING","sponsor":"Chungnam National University Hospital","startDate":"2021-07-06","conditions":["Colon Cancer Stage III"],"enrollment":308,"completionDate":"2031-03-15"},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":["Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":351,"completionDate":"2028-04-22"},{"nctId":"NCT07483359","phase":"PHASE2","title":"Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03","conditions":["Hepatocellular Carcinoma (HCC)","Portal Vein Tumor Thrombus"],"enrollment":38,"completionDate":"2028-05"},{"nctId":"NCT05379595","phase":"PHASE1,PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":["Advanced or Metastatic Colorectal Cancer"],"enrollment":225,"completionDate":"2030-10-31"},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":["Central Nervous System Lymphoma"],"enrollment":58,"completionDate":"2027-11"},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":["Ewing Sarcoma"],"enrollment":321,"completionDate":"2026-12"},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":41,"completionDate":"2027-06-20"},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":["Esophageal Neoplasms","Gastro-esophageal Junction Cancer"],"enrollment":106,"completionDate":"2024-02-09"},{"nctId":"NCT07011576","phase":"PHASE2","title":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-09-29","conditions":["Colon Cancer","Rectal Cancer","Colorectal Cancer","Colorectal Cancer (CRC)"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT05702229","phase":"PHASE2","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-01-16","conditions":["Gastric Cancer"],"enrollment":163,"completionDate":"2029-05-31"},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":["Colorectal Cancer"],"enrollment":200,"completionDate":"2027-02-26"},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":["Colorectal Cancer"],"enrollment":180,"completionDate":"2028-02-28"},{"nctId":"NCT06469944","phase":"PHASE1,PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"enrollment":160,"completionDate":"2029-09-12"},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":["Colorectal Neoplasms"],"enrollment":400,"completionDate":"2029-07-27"},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":["Unresectable Pancreatic Cancer"],"enrollment":90,"completionDate":"2027-05-31"},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":["Locally Advanced Rectal Carcinoma"],"enrollment":394,"completionDate":"2034-03-02"},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":25,"completionDate":"2028-01-31"},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":["Colorectal Cancer"],"enrollment":89,"completionDate":"2011-09"},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06131840","phase":"PHASE1","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-11-20","conditions":["Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung","Stomach Neoplasms","Pancreatic Ductal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Small Cell Lung Carcinoma"],"enrollment":914,"completionDate":"2030-09-12"},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2029-03-11"},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":750,"completionDate":"2030-01"},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":["Advanced Esophageal Squamous Cell Carcinoma","Unresectable Esophageal Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2029-06-30"},{"nctId":"NCT06731803","phase":"PHASE1,PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":["Esophagogastric Adenocarcinoma"],"enrollment":36,"completionDate":"2027-12-31"},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":["Pancreatic Cancer Resectable"],"enrollment":30,"completionDate":"2029-01-31"},{"nctId":"NCT05968326","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-18","conditions":["Adenocarcinoma, Pancreatic Ductal"],"enrollment":260,"completionDate":"2031-01-01"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":["Colo-rectal Cancer"],"enrollment":2,"completionDate":"2026-12-04"},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":["Leukemia"],"enrollment":171,"completionDate":"2026-03-03"},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":500,"completionDate":"2028-09-30"},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":["Colorectal Neoplasms"],"enrollment":100,"completionDate":"2028-09-19"},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":100,"completionDate":"2028-09-06"},{"nctId":"NCT06780111","phase":"PHASE1,PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":298,"completionDate":"2032-01-04"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":20,"completionDate":"2027-06"},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":["Metastatic Adenocarcinoma of the Pancreas"],"enrollment":770,"completionDate":"2025-02-18"},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":1007,"completionDate":"2025-04-23"},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":["Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Stage I Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer"],"enrollment":46,"completionDate":"2024-01-14"},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":["Unresectable Colorectal Cancer"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07070466","phase":"PHASE2","title":"Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-10","conditions":["Stomach Cancer Stage IV","Esophagus Cancer","Stomach Cancer"],"enrollment":40,"completionDate":"2028-09-01"},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":120,"completionDate":"2025-04-23"},{"nctId":"NCT05346484","phase":"PHASE1","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-05-17","conditions":["Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","Metastatic Cancer","Advanced Solid Tumor","Cholangiocarcinoma","Bile Duct Cancer"],"enrollment":66,"completionDate":"2026-01-12"},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":["Pancreatic Cancer"],"enrollment":84,"completionDate":"2028-12-31"},{"nctId":"NCT06279130","phase":"PHASE2,PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":["Resectable MMR-deficient Solid Tumors","Resectable MMR-proficient Solid Tumors"],"enrollment":133,"completionDate":"2034-01-29"},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":["Colorectal Cancer"],"enrollment":528,"completionDate":"2029-06-01"},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":["Metastatic Pancreatic Adenocarcinoma","Recurrent Pancreatic Carcinoma","Stage IV Pancreatic Cancer AJCC v6 and v7"],"enrollment":123,"completionDate":"2026-03-17"},{"nctId":"NCT05677490","phase":"PHASE3","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-31","conditions":["Advanced Esophageal Adenocarcinoma","Advanced Gastric Adenocarcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Unresectable Esophageal Adenocarcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma"],"enrollment":382,"completionDate":"2028-11-08"},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":["Metastatic Pancreatic Cancer"],"enrollment":162,"completionDate":"2027-10-30"},{"nctId":"NCT05568095","phase":"PHASE3","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-11-21","conditions":["Advanced Upper Gastrointestinal Tract Adenocarcinoma"],"enrollment":1040,"completionDate":"2026-06"},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":["Colorectal Adenocarcinoma"],"enrollment":560,"completionDate":"2029-01-07"},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":["Esophagogastric Cancer","HER2-Negative"],"enrollment":39,"completionDate":"2027-02"},{"nctId":"NCT05846867","phase":"PHASE1,PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":["Colorectal Cancer"],"enrollment":170,"completionDate":"2026-08-11"},{"nctId":"NCT07446322","phase":"PHASE2","title":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2026-04-30","conditions":["Ras-mutated Metastatic Colorectal Cancer","mCRC","MSS Metastatic Colorectal Cancer"],"enrollment":60,"completionDate":"2030-04-30"},{"nctId":"NCT05174169","phase":"PHASE2,PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":["Stage III Colon Cancer"],"enrollment":1912,"completionDate":"2030-03-10"},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":["Rectal Cancer"],"enrollment":582,"completionDate":"2029-06-01"},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":["Colorectal Adenocarcinoma"],"enrollment":455,"completionDate":"2026-07-01"},{"nctId":"NCT07446465","phase":"PHASE4","title":"FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ye Xu","startDate":"2026-03-01","conditions":["Colorectal Cancer (Locally Advanced or Metastatic)","Colorectal Cancer Microsatellite Stable (MSS)"],"enrollment":42,"completionDate":"2027-01-31"},{"nctId":"NCT07228832","phase":"PHASE3","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Summit Therapeutics","startDate":"2025-11-18","conditions":["Metastatic Colorectal Cancer (CRC)"],"enrollment":600,"completionDate":"2029-11-30"},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":["Metastatic Colorectal Cancer"],"enrollment":542,"completionDate":"2030-08-31"},{"nctId":"NCT06047379","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":["Diffuse Astrocytoma, IDH-Mutant","Glioblastoma, IDH-wildtype","Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Solid Malignant Tumor","Microsatellite Instability-High Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"enrollment":134,"completionDate":"2027-08-31"},{"nctId":"NCT04068610","phase":"PHASE1,PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":["Metastatic Microsatellite-stable Colorectal Cancer"],"enrollment":61,"completionDate":"2026-11-24"},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":["Liver Metastases From Colorectal Cancer (mCRC)"],"enrollment":16,"completionDate":"2027-02-28"},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":["Solid Tumor"],"enrollment":681,"completionDate":"2027-12-31"},{"nctId":"NCT05083481","phase":"PHASE1,PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":["Advanced Solid Tumors"],"enrollment":366,"completionDate":"2028-05-31"},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":60,"completionDate":"2027-04"},{"nctId":"NCT06452602","phase":"PHASE2","title":"Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-19","conditions":["Esophageal Cancer"],"enrollment":60,"completionDate":"2027-06-01"},{"nctId":"NCT07412613","phase":"PHASE3","title":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2026-03-15","conditions":["Resectable Colon Cancer","MSI-H/dMMR Colorectal Cancer"],"enrollment":386,"completionDate":"2031-03-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Capsule, Injection, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Pyrimethamine Leucovorin"},{"form":"CAPSULE, DELAYED RELEASE PELLETS","route":"ORAL","productName":"EnBrace HR"},{"form":"CAPSULE, DELAYED RELEASE PELLETS","route":"ORAL","productName":"EnLyte"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Leucovorin calcium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Leucovorin Calcium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Leucovorin Calcium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"leucovorin calcium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAMUSCULAR","productName":"LEUCOVORIN CALCIUM"},{"form":"TABLET","route":"ORAL","productName":"LEUCOVORIN CALCIUM"},{"form":"TABLET","route":"ORAL","productName":"Leucovorin Calcium"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147887","MMSL":"1728","NDDF":"001050","UNII":"Q573I9DVLP","VUID":"4019798","CHEBI":"CHEBI:15640","VANDF":"4018768","INN_ID":"690","RXNORM":"225852","UMLSCUI":"C0023413","chemblId":"CHEMBL1201138","ChEMBL_ID":"CHEMBL1679","KEGG_DRUG":"D01211","DRUGBANK_ID":"DB00650","PUBCHEM_CID":"135403648","SNOMEDCT_US":"126223008","IUPHAR_LIGAND_ID":"4816","SECONDARY_CAS_RN":"1492-18-8","MESH_DESCRIPTOR_UI":"D002955"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pfizer","relationship":"Current Owner"},{"period":"2021","companyName":"Pfizer Japan Inc","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.3 hours","clearance":"5.8 mL/min/kg","bioavailability":"4%","fractionUnbound":"0.087%","volumeOfDistribution":"0.25 L/kg"},"publicationCount":7335,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"V03AF03","allCodes":["V03AF03","V03AF06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":26,"_genericFilersChecked":true,"genericManufacturerList":["Abic","Abraxis Pharm","Am Regent","Ani Pharms","Barr","Elkins Sinn","Epic Pharma Llc","Fresenius Kabi Usa","Gland","Glaxosmithkline","Hainan Poly","Hikma","Hospira","Ingenus Pharms Llc","Leading","Meitheal","Mylan Labs Ltd","Novast Labs","Par Pharm","Pharmachemie","Pharmachemie Usa","Sagent Pharms","Sagent Pharms Inc","Teva Parenteral","Teva Pharms Usa","Xanodyne Pharm"],"status":"active","companyName":"Hospira","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"1952","enrichmentLevel":4,"visitCount":5,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1952-06-20T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-05-31T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA089384"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-04-07T00:00:00.000Z","mah":"BARR","brand_name_local":null,"application_number":"ANDA071198"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-26T00:00:00.000Z","mah":"SAGENT PHARMS INC","brand_name_local":null,"application_number":"ANDA209110"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-14T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA207241"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-27T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA207226"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2021-11-25T00:00:00.000Z","mah":"PFIZER JAPAN INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"GLAXOSMITHKLINE","brand_name_local":"WELLCOVORIN","application_number":"ANDA089833"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"GLAXOSMITHKLINE","brand_name_local":"WELLCOVORIN","application_number":"ANDA089834"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":8,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:59.953393+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}